Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cary O Harding

Showing results (81-90 of 113) with videos related to

Pageof 12
Sort By:
Stem Cell Research|June 1, 2014
Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver diseaseRaymond D Hickey, Shennen A Mao, Jaime Glorioso, et al.
Molecular Genetics and Metabolism|February 8, 2014
Infants suspected to have very-long chain acyl-CoA dehydrogenase deficiency from newborn screeningJ Lawrence Merritt, Sverre Vedal, Jose E Abdenur, et al.
Nutrients|September 28, 2023
Expert Consensus on the Long-Term Effectiveness of Medical Nutrition Therapy and Its Impact on the Outcomes of Adults with PhenylketonuriaJúlio César Rocha, Kirsten K Ahring, Heather Bausell, et al.
Molecular Genetics and Metabolism Reports|November 24, 2021
A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trialsBarbara K Burton, Anne Skalicky, Christoph Baerwald, et al.
Ophthalmic Genetics|January 30, 2024
A proposal for an updated staging system for LCHADD retinopathyNida Wongchaisuwat, Melanie B Gillingham, Paul Yang, et al.
Molecular Genetics and Metabolism|July 26, 2024
Initial results from the PHEFREE longitudinal natural history study: Cross-sectional observations in a cohort of individuals with phenylalanine hydroxylase (PAH) deficiencyShawn E Christ, Georgianne Arnold, Uta Lichter-Konecki, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2012
In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type miceNicole K Paulk, Karsten Wursthorn, Annelise Haft, et al.
Journal of Neurochemistry|April 1, 2006
Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiencySven W Sauer, Jürgen G Okun, Gert Fricker, et al.
Molecular Genetics and Metabolism Reports|May 2, 2024
Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial programCary O Harding, Nicola Longo, Hope Northrup, et al.
Ebiomedicine|October 28, 2018
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trialsSoumi Gupta, Kelly Lau, Cary O Harding, et al.
Pageof 12

Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Stem Cell Research|June 1, 2014
Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver diseaseRaymond D Hickey, Shennen A Mao, Jaime Glorioso, et al.
Molecular Genetics and Metabolism|February 8, 2014
Infants suspected to have very-long chain acyl-CoA dehydrogenase deficiency from newborn screeningJ Lawrence Merritt, Sverre Vedal, Jose E Abdenur, et al.
Nutrients|September 28, 2023
Expert Consensus on the Long-Term Effectiveness of Medical Nutrition Therapy and Its Impact on the Outcomes of Adults with PhenylketonuriaJúlio César Rocha, Kirsten K Ahring, Heather Bausell, et al.
Molecular Genetics and Metabolism Reports|November 24, 2021
A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trialsBarbara K Burton, Anne Skalicky, Christoph Baerwald, et al.
Ophthalmic Genetics|January 30, 2024
A proposal for an updated staging system for LCHADD retinopathyNida Wongchaisuwat, Melanie B Gillingham, Paul Yang, et al.
Molecular Genetics and Metabolism|July 26, 2024
Initial results from the PHEFREE longitudinal natural history study: Cross-sectional observations in a cohort of individuals with phenylalanine hydroxylase (PAH) deficiencyShawn E Christ, Georgianne Arnold, Uta Lichter-Konecki, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2012
In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type miceNicole K Paulk, Karsten Wursthorn, Annelise Haft, et al.
Journal of Neurochemistry|April 1, 2006
Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiencySven W Sauer, Jürgen G Okun, Gert Fricker, et al.
Molecular Genetics and Metabolism Reports|May 2, 2024
Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial programCary O Harding, Nicola Longo, Hope Northrup, et al.
Ebiomedicine|October 28, 2018
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trialsSoumi Gupta, Kelly Lau, Cary O Harding, et al.
Pageof 12